kisqali femara co-pack (copackaged)

How long does Letrozole and Ribociclib Succinate stay in your body?

The elimination half-life of letrozole and ribociclib succinate is about 2 days (terminal elimination half-life) — the time it takes the body to clear about half of it. As a rule of thumb, a medicine is mostly gone after roughly 4 to 5 half-lives, though this varies from person to person with age and kidney or liver function. This is the terminal (elimination) half-life; the label states it directly and does not report a separate distribution phase. Letrozole is NOT a prodrug and has NO active metabolite that outlasts it — its main metabolite (the carbinol metabolite, 4,4'-methanol-bisbenzonitrile) is explicitly pharmacologically inactive, so there is no longer-lasting active moiety to report. Note that steady state on daily 2.5 mg dosing is not reached for 2 to 6 weeks. Population effects per the label: AGE — no change in pharmacokinetics was seen with increasing age (adults 35 to >80 years). KIDNEY — renal impairment (creatinine clearance down to ~9-20 mL/min) had no effect on letrozole pharmacokinetics or steady-state levels. LIVER — moderate hepatic impairment (Child-Pugh B) raised exposure (AUC) ~37% (still within the normal range), but severe impairment (Child-Pugh C, cirrhosis) roughly doubled exposure with a 47% drop in systemic clearance, so half-life/exposure is meaningfully prolonged in severe liver disease.

This is general information, not medical advice. It doesn’t tell you when a drug test would read negative (tests detect substances for different, often longer, windows) or when it’s safe to take another dose — ask your pharmacist or prescriber. Source: Letrozole tablet — DailyMed label, Section 12.3 Pharmacokinetics.

Frequently asked questions

How is Kisqali Femara Co-Pack (Copackaged) rated?

pharmaranks gives Kisqali Femara Co-Pack (Copackaged) a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.

How much does Kisqali Femara Co-Pack (Copackaged) cost?

Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $4.37 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins. Pharmacies pay less for a same-class option, Mysoline — about $2.89 on the same basis.

Is there a coupon or discount for Kisqali Femara Co-Pack (Copackaged)?

pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Kisqali Femara Co-Pack (Copackaged). To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.

Who makes Kisqali Femara Co-Pack (Copackaged)?

Kisqali Femara Co-Pack (Copackaged) is marketed by Novartis. You can see Novartis's full profile, rating, and other products on pharmaranks.

Is Kisqali Femara Co-Pack (Copackaged) a brand-name or generic drug?

Kisqali Femara Co-Pack (Copackaged) is a brand-name product with the active ingredient Letrozole and Ribociclib Succinate.

Is Kisqali Femara Co-Pack (Copackaged) available over the counter?

No. Kisqali Femara Co-Pack (Copackaged) is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.

What forms does Kisqali Femara Co-Pack (Copackaged) come in?

Kisqali Femara Co-Pack (Copackaged) is currently marketed as kit, per the FDA's National Drug Code Directory.

Is Kisqali Femara Co-Pack (Copackaged) FDA-registered?

Kisqali Femara Co-Pack (Copackaged) is on record with the U.S. FDA under application number NDA209935. You can verify this on its official FDA label.

Has Kisqali Femara Co-Pack (Copackaged) been recalled by the FDA?

Kisqali Femara Co-Pack (Copackaged) has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.

Is Kisqali Femara Co-Pack (Copackaged) safe?

There's no single safe-or-not verdict. pharmaranks gives Kisqali Femara Co-Pack (Copackaged) a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.